| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
KYV-101 IIT data demonstrate promising clinical activity, including robust CAR T penetration into the central nervous system (CNS) and improved expanded disability status scale scores (EDSS)
KYV-101 continues to demonstrate a tolerable safety profile, consistent with observations from the first 100 patients treated with KYV-1011
Encouraging early data of KYV-101 in multiple sclerosis highlights broader potential within neuroimmunology autoimmune diseases
EMERYVILLE, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced updated data from Phase 1 investigator-initiated trials (IITs) of KYV-101 in the treatment of progressive multiple sclerosis (MS) to be presented at the 2025 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress, taking place in Barcelona, Spain from September 24-26, 2025. Data presented will include an oral presentation from Stanford Medicine (Stanford), Department of Neurology & Neurological Sciences and a poster presentation from the University of California, San Francisco (UCSF), Weill Institute for Neurosciences.
Posted In: KYTX
